Key Proteo
Key Proteo develops innovative newborn screening technology for early genetic disease detection, improving patient life quality.
Founded
2019Key Proteo develops innovative newborn screening technology for early genetic disease detection, improving patient life quality.
Key Proteo, founded with a mission to revolutionize newborn screening, focuses on the early detection of genetic diseases through innovative peptide screening technology. The company's vision is to enhance and expand current newborn screening programs, enabling early intervention before diseases manifest clinically. Specializing in multiplex analysis of low-abundance proteins from dried blood spots using mass spectrometry, Key Proteo aims to address both new and existing genetic conditions, improving patient outcomes and quality of life.
Notable figures affiliated with Key Proteo include leading experts in neuroscience and genetic research. The company has garnered attention from prominent investors in the biotech sector, reflecting confidence in its groundbreaking technology. Key achievements include the development of a highly sensitive and specific screening method that has the potential to transform newborn healthcare. Overall, Key Proteo's impact lies in its commitment to saving lives and reducing the burden of genetic disorders through early and accurate diagnosis.
Companies similar to Key Proteo include Spear Bio, Encodia, Proteogenix and ProteoNova.
Key Proteo was founded in 2019.
Key Proteo's headquarters is located in Seattle, WA, US.
Key Proteo's most recent funding round was for $3M (USD) in May 2023.
As of May 16, 2023, Key Proteo has disclosed funding of $3M (USD). Undisclosed round amounts are excluded.
Key Proteo has 6 employees as of Feb 5, 2024.
proteonova.com
